"id","name","instanceType","rationale","uuid:ID","label","description"
"StudyDesign_1","Study Design 1","StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","ea362561-4267-4e2f-b9ee-96764bad6da9","","The main design for the study"
